Journal Article

DZNE-2020-03585

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Increased myeloperoxidase plasma levels in patients with Alzheimer's disease.

Tzikas, S. ; Schlak, D. ; Sopova, K. ; Gatsiou, A. ; Stakos, D. ; Stamatelopoulos, K. ; Stellos, K. (Corresponding author) ; Laske, C. (Last author)DZNE*

2014
IOS Press Amsterdam

This record in other databases:    

Please use a persistent id in citations: doi:10.3233/JAD-131469

Abstract: Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer’s disease (AD).Objective:In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible association with plasma amyloid-β (Aβ)1-42/1-40 ratio in AD patients and elderly healthy controls.Methods:The study sample included 28 AD patients and 27 elderly individuals with a normal cognitive status as a control group. The Mini-Mental Status Examination was used to determine the global cognition. MPO, Aβ1-40, and Aβ1-42 plasma concentrations were measured by enzyme linked immunoabsorbent assays.Results:AD patients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean ± SD): 132.8 ± 114.8 ng/mL versus 55.0 ± 42.6 ng/mL; p = 0.002). MPO plasma concentrations showed a significant positive correlation in the whole sample with the presence of AD (ρ = 0.428, p < 0.001) and its stage (ρ = 0.331; p = 0.013) as well as with plasma concentrations of Aβ1-42 (ρ = 0.406; p = 0.004) and Aβ1-42/1-40 ratio (ρ = 0.354; p = 0.013). In a binary logistic regression model, plasma MPO concentrations were independently associated with the presence of AD (p = 0.014).Conclusion:AD patients showed significantly increased plasma levels of MPO, which could be an important molecular link between atherosclerosis and AD. Further studies should evaluate whether MPO may also be a useful biomarker and potential new treatment target in AD.

Keyword(s): Aged (MeSH) ; Aged, 80 and over (MeSH) ; Alzheimer Disease: blood (MeSH) ; Amyloid beta-Peptides: blood (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Immunoenzyme Techniques (MeSH) ; Logistic Models (MeSH) ; Male (MeSH) ; Mental Status Schedule (MeSH) ; Neuropsychological Tests (MeSH) ; Peptide Fragments: blood (MeSH) ; Peroxidase: blood (MeSH) ; ROC Curve (MeSH) ; Amyloid beta-Peptides ; Peptide Fragments ; amyloid beta-protein (1-40) ; amyloid beta-protein (1-42) ; Peroxidase

---

Contributing Institute(s):

1. Cell Biology of Neurological Diseases (AG Jucker)

Research Program(s):

1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2014

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---